IBRX (ImmunityBio Inc.) stock: $6.65, $7.05B market cap, $334.3M cash, $6.72B EV, $8.16B fully diluted market cap. Next expected readout: Nov-26. Lead program: N-803 and BCG (Bladder Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield ™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist, ANKTIVA ® (nogapendekin alfa inbakicept).
Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.
Share structure
Common
1,059.8M
Pre-funded warrants
0.0M
Options
23.6M
RSUs
5.9M
Warrants
49.5M
Converts
88.4M
Conv preferred
0.0M
ESPP reserve
—
FDSO
1,227.3M
Cap table as of 2026-08-04.
Price history
Loading IBRX daily closes…
Loading price history…
Next catalyst
ANKTIVA · Est. Nov 11, 2026 · PCD + 6 wks · guided Now
Recently reported
Nogapendekin alfa inbakiceptPositive · 2026-11-09
N-803
Primary: Primary endpoint in Cohort A of QUILT-2.005 in BCG-naive high-grade NMIBC with carcinoma in situ, with or without papillary tumors (release does not state the numeric measure) — ANKTIVA plus BCG met the primary efficacy endpoint, demonstrating a statistically significant improvement in efficacy compared with BCG alone; numeric response rates were not disclosed in the release
· 370 randomized patients
· More than 75 clinical trial sites
· Database lock October 20, 2026
· Median duration of response had not yet been reached
· Supplemental BLA on track for FDA submission by year-end 2026
Safety: Most common treatment-emergent adverse events consistent with BCG alone; no treatment-related deaths reported
HPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Approved · ActiveModality: IL-15 receptor superagonist antibody-cytokine fusion protein
Aliases N-803
Target IL-15 receptor
Partnerships Serum Institute (partnership); BeOne (collaboration, Jan 2025); international partners for EU and Middle East/North Africa commercialization
Indications
BCG-unresponsive NMIBC with CIS (with or without papillary tumors)(Approved)
BCG-unresponsive NMIBC with papillary tumors without CIS(Phase 3)
BCG-naive NMIBC CIS (with or without papillary tumors)(Phase 2)
NSCLC(Stage not disclosed)
Indolent non-Hodgkin lymphoma incl. Waldenstrom macroglobulinemia(Stage not disclosed)
Colorectal cancer(Stage not disclosed)
Catalysts
— January 6, 2027
— 2026
Status note FDA approved Apr 2024 (J-code Jan 2025); approved/authorized in 5 jurisdictions (34 countries). NCI evaluating ANKTIVA in Lynch syndrome cancer prevention study.
Multiply relapsed locally advanced/metastatic pancreatic cancer (with ANKTIVA)(Phase 2)
Status note ANKTIVA + PD-L1 t-haNK: recurrent GBM Phase 2 complete, registrational trial planned; pancreatic cancer Phase 2 (FDA RMAT designation for ANKTIVA + PD-L1 t-haNK with chemo/radiotherapy for lymphopenia reversal and treatment of multiply relapsed pancreatic cancer).
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma
—
Sponsor-matched active trials from ClinicalTrials.gov (21 as sponsor, 6 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.